A Phase III trial of OMS 721 for stem cell transplant-associated thrombotic microangiopathy
Phase of Trial: Phase III
Latest Information Update: 22 Jan 2018
At a glance
- Drugs OMS 721 (Primary)
- Indications Thrombotic microangiopathy
- Focus Therapeutic Use
- 22 Jan 2018 According to an Omeros corporation media release, this trial is expexcted to initiate in the first half of 2018.
- 20 Oct 2017 According to an Omeros corporation media release, company is planning to initiate this trial later this year.
- 04 Apr 2017 New trial record